DDInter1042 DDInter1553
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable option for some patients with high sensitivity to other drugs, such as [clozapine] and [olanzapine].
Quetiapine {u} (Compound) resembles {v} (Compound) Trazodone
Quetiapine {u} (Compound) binds {v} (Gene) DRD5
Quetiapine {u} (Compound) upregulates {v} (Gene) SLC11A2
Quetiapine {u} (Compound) palliates {v} (Disease) autistic disorder
Quetiapine {u} (Compound) downregulates {v} (Gene) TM9SF2
Quetiapine {u} (Compound) causes {v} (Side Effect) Salivary hypersecretion
Quetiapine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Quetiapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sitagliptin
Quetiapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diphenhydramine
Quetiapine {u} may lead to a major life threatening interaction when taken with {v} Clarithromycin
Quetiapine (Compound) resembles Trazodone (Compound)
Quetiapine (Compound) binds DRD5 (Gene)
Quetiapine (Compound) upregulates SLC11A2 (Gene)
Quetiapine (Compound) palliates autistic disorder (Disease)
Quetiapine (Compound) downregulates TM9SF2 (Gene)
Quetiapine (Compound) causes Salivary hypersecretion (Side Effect)
Quetiapine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin
Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine
Quetiapine may lead to a major life threatening interaction when taken with Clarithromycin